Suppr超能文献

欧盟微生物农药的人体健康风险评估:挑战与展望

Human health risk assessment for microbial pesticides in the EU: challenges and perspectives.

作者信息

Barrero-Canosa Jimena, Ebeling Julia, Kenny Elaine F, Marx-Stoelting Philip, Paege Norman, Feustel Sabrina, Leme Daniela Morais

机构信息

German Federal Institute for Risk Assessment (BfR), Berlin, Germany.

Department of Genetics, Federal University of Paraná (UFPR), Curitiba, PR, Brazil.

出版信息

Environ Health. 2025 Jul 2;24(1):43. doi: 10.1186/s12940-025-01196-1.

Abstract

The risk assessment of microbial pesticides in the European Union (EU) is covered by a regulatory framework based on EU Regulation 1107/2009 and 546/2011 together with the data requirements in EU Regulation 283/2013 and 284/2013, Part B, respectively (all amended in 2022). Furthermore, several guidance documents specify the data requirements for the human health assessment. As in other regulatory contexts, the assessment of hazardous properties of a microbial plant protection product (PPP) can be based on in vivo data. In order to decrease the use of test animals, support high-throughput data generation with larger repetition, and to facilitate faster testing methods, New Approach Methodologies (NAMs) for this field need to be developed. Here we focus on the assessment of the potential pathogenicity/infectivity and the presence of transferable antimicrobial resistance (AMR) genes of a microorganism when utilised as the active substance (AS) in a PPP. For the purpose of risk assessment of microbial PPPs, NAMs developed in view of the Next Generation Risk Assessment (NGRA) for chemicals can be applied. However, major drawbacks in the ability to use existing NAMs in the risk assessment of microbial pesticides are the reliability of Adverse Outcome Pathway (AOP) generated data for humans and the practicability of in vitro methods to test living microorganisms. It must be emphasised that tests for risk assessment are only useful if the test interpretation is clearly defined. Without prior definition of the possible effects and their interpretation, including the possible outcome for risk assessment, the test has limited value, as the results may raise more questions than answers. Overall, the regulatory assessment of the human health effects of microbial pesticides used in PPP needs reliable and robust data. These data should ideally be presented by an applicant based on animal-free study setups together with thorough literature searches.

摘要

欧盟(EU)对微生物农药的风险评估涵盖在基于欧盟法规1107/2009和546/2011以及欧盟法规283/2013和284/2013 B部分(均于2022年修订)的数据要求的监管框架内。此外,一些指导文件规定了人类健康评估的数据要求。与其他监管情况一样,微生物植物保护产品(PPP)的有害特性评估可以基于体内数据。为了减少实验动物的使用,支持更大重复次数的高通量数据生成,并促进更快的测试方法,需要开发该领域的新方法(NAMs)。在这里,我们专注于评估微生物作为PPP中的活性物质(AS)时的潜在致病性/感染性以及可转移的抗菌抗性(AMR)基因的存在情况。出于微生物PPP风险评估的目的,可以应用鉴于化学品下一代风险评估(NGRA)而开发的NAMs。然而,在微生物农药风险评估中使用现有NAMs的能力的主要缺点是针对人类生成的不良结局途径(AOP)数据的可靠性以及测试活微生物的体外方法的实用性。必须强调的是,只有在明确界定测试解释的情况下,风险评估测试才有用。如果没有事先定义可能的影响及其解释,包括风险评估的可能结果,测试的价值就有限,因为结果可能提出的问题比答案还多。总体而言,对PPP中使用的微生物农药的人类健康影响进行监管评估需要可靠和稳健的数据。理想情况下,这些数据应由申请人基于无动物研究设置并结合全面的文献检索来提供。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验